Podcast Episodes
Back to Search
Episode 8: Pulling the Goalie on FLT3 Inhibitor Use in AML - A Discussion with Dr. Dale Bixby
Season 1 Episode 8
In this enlightening episode, Anthony and Bernie chat about FLT3+ AML with Dr. Dale Bixby, Clinical Professor and expert in leukemia at the University of Michigan. We use two clinical cases to take a…
Published on 2 years, 9 months ago
Episode (3+)7: Straight Outta Roswell - OG AML Data
Season 1 Episode 7
Finally back from a much needed vacation, in this episode, Anthony and Bernie discuss some of the "OG" data and pharmacology behind key AML therapies.
Published on 2 years, 11 months ago
Episode 6: Dr. StrangeDrug or: How I Learned to Stop Worrying and Love the Asparaginase
Season 1 Episode 6
In this episode, Bernie and Anthony do an in-depth dive into the pharmacology, toxicity management, and clinical conundrums with asparaginase therapy, including how and when to monitor asparaginase a…
Published on 3 years, 1 month ago
Episode 5: IDH Inhibitors in AML: not so AGILE
Season 1 Episode 5
In this episode, Bernie Marini and Anthony Perissinotti chat with special guest Charles Foucar, MD, a hematology specialist and expert in the field. We discuss the controversial FDA approval of ivosi…
Published on 3 years, 3 months ago
Episode 4: All Aboard the Oncology StewardSHIP
In this episode, Bernie Marini and Anthony Perissinotti are joined by two special guest hematology experts - Lydia Benitez, PharmD, BCOP, and Madeleine Ochs, PharmD, BCOP. Maddy and Lydia help us div…
Published on 3 years, 3 months ago
Episode 3.2: Ranting About Rituximab in Acute Lymphoblastic Leukemia
Season 1 Episode 3
In part two of this two-part episode, Bernie Marini and Anthony Perissinotti discuss the use of rituximab in acute lymphoblastic leukemia (ALL), based on the recent publication of the UKALL14 study (…
Published on 3 years, 4 months ago
Episode 3.1: History of Acute Lymphoblastic Leukemia Treatment and Building the BFM Backbone
Season 1 Episode 3
In part one of a two-part episode, Bernie Marini and Anthony Perissinotti take a journey through the history of acute lymphoblastic leukemia treatment throughout the decades and explain how we got to…
Published on 3 years, 4 months ago
Episode 2: We Don't Talk About Rylaze
Season 1 Episode 2
Bernie Marini and Anthony Perissinotti discuss asparaginase, the data (or lack thereof) behind the FDA approval of Rylaze (Erwinia asparaginase), and concerning trends regarding switches between aspa…
Published on 3 years, 5 months ago
Episode 1: Surrogate Endpoints in AML
Season 1 Episode 1
Bernie Marini and Anthony Perissinotti discuss the following paper on whether or not event-free survival (EFS) is an appropriate surrogate endpoint for overall survival (OS) in AML:
Norsworthy KJ, e…
Published on 3 years, 6 months ago